Skip to main content
Funded Studies

Andreas Weiss, PhD

Director of Drug Discovery and Technologies at IRBM PROMIDIS

Location: Pomezia Italy

Andreas Weiss, PhD, was laboratory head and project leader for Protein Homeostasis Disorders at the Novartis Institutes for Biomedical Research in Basel, Switzerland. During his seven years at Novartis he developed innovative biochemical assays and identified targets in several neurodegenerative disorders. He was project leader of a collaboration with CHDI (the Cure Huntington‘s Disease Initiative) focusing on huntingtin protein detection technologies and developed the first conformer-specific huntingtin and alpha-synuclein bioassays for high-throughput screening, translational research, biomarker application and clinical studies. He studied biochemistry, immunology and neuroendocrinology at the University of Bielefeld, Germany; the University of Notre Dame, USA; and the Max Planck Institute for Experimental Endocrinology, Germany. He received his PhD in neurobiology from the University of Basel for his work on “Novel methods and therapeutic approaches of diagnosis and treatment of Huntington’s disease.” He collaborated with key-opinion leaders in the field of pre-clinical and clinical Huntington’s disease and Parkinson’s disease research and has over 20 peer-reviewed publications.

Associated Grants

  • Assay-PoC for the Reduction of Endogenous Alpha-synuclein Levels in iPS-PD Neurons


  • Development of Highly Sensitive Immunoassays for pS129 Alpha-synuclein in Human Samples


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.